Johnsen KB, Burkhart A, Melander F et al (2017) Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma
GLP-1 agonism is a mechanism of action typically not used by these drugs, and in the context of Eriomin, it appears to be a relatively safe mechanism, as no significant adverse effects were reported in this study or the other clinical study
This article covers the specific storage timelines for various GLP-1 (glucagon-like peptide-1) medications, including semaglutide and tirzepatide
You are what you eat: Diet, health and the gut microbiota
Additionally, impaired leptin regulation in the liver disrupts satiety signals, driving overeating and creating a vicious cycle
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD